The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Current Guidelines for Hypertension Control and Choice of Antihypertensive Drugs

고혈압의 최신진료지침과 약제선택

  • Jeong, Jin-Won (Division of Cardiology, Department of Internal Medicine, Wonkwang University College of Medicine)
  • 정진원 (원광대학교 의과대학 내과학교실)
  • Published : 2011.03.01
⟨ Previous Next ⟩

Abstract

According to the mata-analysis on the management of hypertension and guidelines published in recent years concluded that the amount of blood pressure reduction, not the choice of antihypertensive drug is the major determinant of reduction in cardiovascular morbidity and mortality in the both younger and older partients with hypertension. However still remained the some patients having an indication for a specific drug or drugs that is helpful to those of the patients with diabetes, chronic kidney disease, ischemic heart disease, heart failure or atrial fibrillation. Thus, individualized, tailored drug therapy would be preferred to stepped care approach in the management of essential hypertension.

Keywords

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572. https://doi.org/10.1001/jama.289.19.2560
  2. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from American heart association councils for high blood pressure research and councils on clinical caldiology and epidemiology and prevention. Circulation 2007; 115:2761-2788. https://doi.org/10.1161/CIRCULATIONAHA.107.183885
  3. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial htypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
  4. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
  5. The antihypertensive and lipid-lowering treatment to prevent heart attack trial Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997. https://doi.org/10.1001/jama.288.23.2981
  6. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47: 352-358. https://doi.org/10.1161/01.HYP.0000203309.07140.d3
  7. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801.
  8. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428. https://doi.org/10.1056/NEJMoa0806182
  9. Williams B, Poulter NR, Brown MJ, et al. British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-640. https://doi.org/10.1136/bmj.328.7440.634
  10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153. https://doi.org/10.1056/NEJM200001203420301
  11. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788. https://doi.org/10.1016/S0140-6736(03)14286-9
  12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3
  13. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
  14. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049-2051. https://doi.org/10.1016/S0140-6736(04)16456-8
  15. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2225. https://doi.org/10.1001/jama.292.18.2217
  16. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1988;279:1903-1907.
  17. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227. https://doi.org/10.1001/jama.292.18.2227
  18. The ONTARGET Investigators. Telmisartan, ramipril , or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. https://doi.org/10.1056/NEJMoa0801317
  19. Mann JF, Schmieder RE, McQeen M, et al. Renal outcomes with telmisartan, ramipril, or both , in people at high vascular risk(the ONTARGET Study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008;372:547-553. https://doi.org/10.1016/S0140-6736(08)61236-2